Skip to main content

Advertisement

SpringerLink
Log in

Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To examine the incidence of secondary primary malignancies in patients with renal cortical neoplasms.

Methods

Between January 1989 and July 2010, 3647 patients underwent surgery at our institution for a renal cortical neoplasm and were followed through 2012. Occurrence of other malignancies was classified as antecedent, synchronous, or subsequent. All patients with antecedent malignancies (n = 498) and a randomly selected half of those with synchronous malignancies (n = 83) were excluded. The expected number of second primaries was calculated by multiplying Surveillance, Epidemiology, and End Results Program incidence rates of renal cortical neoplasms by person-years at risk within categories of age, sex, and year of diagnosis. The standardized incidence ratio (SIR) was calculated as observed cancers divided by expected incidence of the cancer, with approximation to the exact Poisson test used to obtain confidence intervals (CI) and p values.

Results

Of 3066 patients with renal cortical neoplasms, 267 had a second primary cancer; the five most common in men were prostate, colorectal, bladder, lung, and non-Hodgkin’s lymphoma; the five most common in women were breast, colorectal, lung, endometrium, and thyroid. Men demonstrated higher than expected thyroid cancer rate (SIR 5.0; 95 % CI 1.83–10.88, p = 0.002), and women had higher than expected rates of stomach cancer (SIR 5.0; 95 % CI 1.61–11.67, p = 0.004) and thyroid cancer (SIR 4.62; 95 % CI 1.69–10.05, p = 0.003).

Conclusions

The incidence of certain types of second malignancies may be higher in patients after diagnosis of renal cortical neoplasms compared to the general population. These observations can inform clinical follow-up in kidney cancer survivorship and future research studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I et al (2014) Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 8:247–252

    Article  PubMed  PubMed Central  Google Scholar 

  2. De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD, Dryer D (2014) Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986–2007. Cancer Causes Control 25:1271–1281

    Article  PubMed  PubMed Central  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  PubMed  Google Scholar 

  4. Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ (2013) Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol 36:132–142

    Article  PubMed  PubMed Central  Google Scholar 

  5. Beisland C (2013) Letter to the editor. Am J Clin Oncol 36:423

    Article  PubMed  Google Scholar 

  6. Beisland C, Talleraas O, Bakke A, Norstein J (2006) Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 97:698–702

    Article  PubMed  Google Scholar 

  7. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED et al (2006) Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol 176:900–903

    Article  PubMed  Google Scholar 

  8. Rabbani F, Reuter VE, Katz J, Russo P (2000) Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology 56:399–403

    Article  CAS  PubMed  Google Scholar 

  9. Rabbani F, Grimaldi G, Russo P (1998) Multiple primary malignancies in renal cell carcinoma. J Urol 160:1255–1259

    Article  CAS  PubMed  Google Scholar 

  10. Kantor AF, McLaughlin JK, Curtis RE, Flannery JT, Fraumeni JF Jr (1986) Risk of second malignancy after cancers of the renal parenchyma, renal pelvis, and ureter. Cancer 58:1158–1161

    Article  CAS  PubMed  Google Scholar 

  11. Teppo L, Pukkala E, Saxen E (1985) Multiple cancer—an epidemiologic exercise in Finland. J Natl Cancer Inst 75:207–217

    CAS  PubMed  Google Scholar 

  12. Wilson RT, Silverman DT, Fraumeni JF Jr, Curtis RE (2006) New malignancies following cancer of the urinary tract. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (eds) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda, pp 285–312

    Google Scholar 

  13. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP (1995) Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol 142:653–665

    CAS  PubMed  Google Scholar 

  14. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I et al (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277–1288

    Article  PubMed  Google Scholar 

  15. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E et al (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685–691

    Article  PubMed  Google Scholar 

  16. Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281–288

    Article  CAS  PubMed  Google Scholar 

  17. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7:277–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z et al (2006) Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer 6:131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H (2005) MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 29:544–549

    Article  PubMed  Google Scholar 

  20. Montani M, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU et al (2005) No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer 12:1011–1016

    Article  CAS  PubMed  Google Scholar 

  21. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V et al (2000) Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85:1758–1764

    CAS  PubMed  Google Scholar 

  22. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF et al (2015) Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral center. BJU Int. doi:10.1111/bju.13194

    Google Scholar 

  23. Rizzo M, Rossi RT, Bonaffini O, Scisca C, Sindoni A, Altavilla G et al (2009) Thyroid metastasis of clear cell renal carcinoma: report of a case. Diagn Cytopathol 37:759–762

    Article  PubMed  Google Scholar 

  24. Koo HL, Jang J, Hong SJ, Shong Y, Gong G (2004) Renal cell carcinoma metastatic to follicular adenoma of the thyroid gland. A case report. Acta Cytol 48:64–68

    Article  PubMed  Google Scholar 

  25. McCredie M, Macfarlane GJ, Stewart J, Coates M (1996) Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972–91. Cancer Causes Control 7:337–344

    Article  CAS  PubMed  Google Scholar 

  26. Shiels MS, Gibson T, Sampson J, Albanes D, Andreotti G, Beane Freeman L et al (2014) Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. J Clin Oncol 32:3989–3995

    Article  PubMed  PubMed Central  Google Scholar 

  27. Guan HB, Wu QJ, Gong TT (2013) Parity and kidney cancer risk: evidence from epidemiologic studies. Cancer Epidemiol Biomark Prev 22:2345–2353

    Article  Google Scholar 

  28. Karami S, Daugherty SE, Purdue MP (2014) Hysterectomy and kidney cancer risk: a meta-analysis. Int J Cancer 134:405–410

    Article  CAS  PubMed  Google Scholar 

  29. Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd et al (2013) Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993–2010. Am J Epidemiol 177:1368–1377

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ricceri F, Fasanelli F, Giraudo MT, Sieri S, Tumino R, Mattiello A et al (2015) Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 137:940–948

    Article  CAS  PubMed  Google Scholar 

Download references

Author contributions

K.S. Murray was involved in project development and data collection/management and wrote and edited the manuscript. E.C. Zabor was involved in data management and data analysis. M. Spaliviero was involved in protocol/project development and data collection/management and edited the manuscript. P. Russo was involved in protocol/project development and data analysis and edited the manuscript. W.M. Bazzi was involved in protocol/project development. J.E. Musser was involved in data collection/management. A.A. Hakimi was involved in protocol/project development and edited the manuscript. M.L. Bernstein was involved in protocol maintenance and data collection/management. G. Dalbagni was involved in protocol/project development. J.A. Coleman was involved in protocol/project development and wrote and edited the manuscript. H. Furberg was involved in protocol/project development and data analysis and wrote and edited the manuscript.

Funding

The study was supported by Sidney Kimmel Center for Prostate and Urologic Cancers and the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. The Memorial Sloan Kettering investigators gratefully acknowledge the MSK Cancer Center Support Grant/Core Grant (P30 CA008748).

Author information

Authors and Affiliations

  1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Katie S. Murray, Massimiliano Spaliviero, Paul Russo, Wassim M. Bazzi, John E. Musser, A. Ari Hakimi, Melanie L. Bernstein, Guido Dalbagni & Jonathan A. Coleman

  2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Emily C. Zabor & Helena Furberg

  3. Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA

    Paul Russo, A. Ari Hakimi, Guido Dalbagni & Jonathan A. Coleman

Authors
  1. Katie S. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily C. Zabor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimiliano Spaliviero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wassim M. Bazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John E. Musser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ari Hakimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Melanie L. Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guido Dalbagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jonathan A. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Helena Furberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katie S. Murray.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murray, K.S., Zabor, E.C., Spaliviero, M. et al. Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. World J Urol 34, 1667–1672 (2016). https://doi.org/10.1007/s00345-016-1832-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1832-4

Keywords

Search

Navigation